Funding for this research was provided by:
Novartis Healthcare A/S
Received: 30 April 2020
Accepted: 27 May 2020
First Online: 3 June 2020
Ethics approval and consent to participate
: Informed written consent was obtained from each patient before conducting any study-related procedures. The study protocol was reviewed by the Regional Health Research Ethics Committee of the Capital Region of Denmark (identifier: H-18050498).
: Not applicable.
: The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: Dr. Casper Emil Christensen has lectured and been a scientific advisor for Teva. Dr. Messoud Ashina has received personal fees from Alder BioPharmaceuticals, Allergan, Amgen, Eli Lilly, Novartis, and Teva. Dr. Messoud Ashina has been or currently is a principal investigator on clinical trials for Alder, Amgen, electroCore, Novartis, and Teva. Dr. Messoud Ashina also serves as an Associate Editor of Cephalalgia, Associate Editor of Headache, and Co-Editor of the Journal of Headache and Pain. Dr. Messoud Ashina reports research grants from Lundbeck Foundation, Novo Nordisk Foundation, and Research Foundation of the Capital Region of Denmark. Dr. Faisal Mohammad Amin has received personal fees from Eli Lilly, Novartis and Teva. Dr. Faisal Mohammad Amin is currently a principal investigator on clinical trials for Novartis and Teva. Dr. Faisal Mohammad Amin also serves as an Associate Editor of Headache Medicine. Dr. Henrik Winther Schytz has received speaking fees from Novartis and Teva. The other authors declare no conflicts of interest.